# Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

> **NCT00490529** · PHASE2 · COMPLETED · sponsor: **Ronald Levy** · enrollment: 59 (actual)

## Conditions studied

- Lymphoma, Mantle-Cell

## Interventions

- **BIOLOGICAL:** CpG-MCL vaccine
- **BIOLOGICAL:** PF-3512676
- **PROCEDURE:** Vaccine-primed T-cells
- **PROCEDURE:** Autologous hematopoietic stem cell transplant (HSCT)
- **DRUG:** Rituximab
- **DRUG:** Standard induction chemotherapy
- **DRUG:** Cyclophosphamide
- **DRUG:** Filgrastim

## Key facts

- **NCT ID:** NCT00490529
- **Lead sponsor:** Ronald Levy
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2017-12-14
- **Final completion:** 2017-12-14
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2020-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00490529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00490529, "Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00490529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*